Conexeu Sciences Inc. has 10 Schedule 13D or 13G filings on record since 2026-07-20. 8 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Purcell Lynn Sebastian | 12.3% | 3,359,240 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Wright Michael G. | 12.1% | 3,276,643 | SCHEDULE 13G, 2026-07-28 | 2026-06-30 |
| Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund | 9.99% | 4,314,336 | SCHEDULE 13G/A, 2026-09-04 | 2026-06-30 |
| David Bogart | 8.1% | 2,293,750 | SCHEDULE 13G, 2026-08-18 | 2026-06-30 |
| OnePointTwo Capital Ventures LLC | 6.8% | 1,875,000 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Paisley Capital Holdings Corp | 6.7% | 1,800,000 | SCHEDULE 13G, 2026-07-20 | 2026-06-30 |
| OnePointTwo Capital Ventures II LLC | 5.5% | 1,484,240 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Jeffrey Sharpe | 5.2% | 1,500,000 | SCHEDULE 13D/A, 2026-09-15 | 2026-09-14 |
Purpose of Transaction (Item 4)
Jeffrey Sharpe
The information set forth in Items 3, 5 and 6 of this Schedule 13D is incorporated by reference herein. Background On May 14, 2025, the Issuer and 1036030 B.C. Ltd., a company solely owned by the Reporting Person, entered into a consulting services agreement pursuant to which the Reporting Person was granted 2,000,000 Performance Warrants to acquire shares of Common Stock at an exercise price of $0.001 per share, with a term of five years. The Performance Warrants vest contingent upon the occurrence of the following four specified performance milestones: - Milestone 1: 500,000 Performance Warrants shall vest upon the Issuer completing and receiving the results of a three-month collagen study conducted in Boston, Massachusetts; - Milestone 2: 500,000 Performance Warrants shall vest upon the Issuer listing its shares of Common Stock on the Nasdaq Stock Market, LLC, or any other recognized stock exchange in North America; - Milestone 3: 500,000 Performance Warrants shall vest upon the Issuer's listed shares of Common Stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater on a recognized North American stock exchange on which the shares of Common Stock are listed; and - Milestone 4: 500,000 Performance Warrants shall vest upon the Issuer's submission of a 510(k) application to the U.S. Food and Drug Administration. On July 8, 2025, Milestone 1 was achieved upon the Issuer completing and receiving the results of the …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-09-15; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-07-20 | Paisley Capital Holdings Corp | 6.7% | SCHEDULE 13G |
| 2026-07-28 | Wright Michael G. | 12.1% | SCHEDULE 13G |
| 2026-08-14 | OnePointTwo Capital Ventures LLC | 6.8% | SCHEDULE 13G |
| 2026-08-14 | OnePointTwo Capital Ventures II LLC | 5.5% | SCHEDULE 13G |
| 2026-08-14 | Purcell Lynn Sebastian | 12.3% | SCHEDULE 13G |
| 2026-08-18 | David Bogart | 8.1% | SCHEDULE 13G |
| 2026-08-18 | Jeffrey Sharpe | 5.4% | SCHEDULE 13D |
| 2026-09-04 | Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund | 9.99% | SCHEDULE 13G |
| 2026-09-04 | Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund | 9.99% | SCHEDULE 13G/A |
| 2026-09-15 | Jeffrey Sharpe | 5.2% | SCHEDULE 13D/A |
Conexeu Sciences Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Conexeu Sciences Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.